Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Panel hears bill to require validated non‑animal test methods in drug development
Summary
Supporters told the Consumer Protection and Business Committee HB 2542 would require use of validated non‑animal test methods in drug development when available; industry witnesses urged care to avoid hindering research where alternatives are not yet adequate. The committee heard broad public support and staff briefing on federal FDA developments.
The Consumer Protection and Business Committee heard testimony Jan. 27 on House Bill 2542, which would prohibit use of animal test methods in drug development when a validated, non‑animal alternative that provides information of equivalent or better scientific quality is available.
Megan Mulvihill, staff to the committee, told members that the bill defines an alternative test method as one that “provides information of equivalent or better scientific quality and relevance” and is identified by a validation body and adopted by the relevant federal agency. She noted the 2022 federal FDA Modernization Act removed the mandatory…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
